Group 1 - The ChiNext Index has shown strong performance, increasing by 1.58% today and has risen for five consecutive months, indicating a robust trend [2] - The current bull market logic remains unchanged, supported by macroeconomic conditions and liquidity, with structural opportunities clearly defined, favoring growth styles in A-shares [4] - The ChiNext Index is a representative broad-based index of growth style, focusing on emerging industries, with significant highlights in its top three sectors: technology, pharmaceuticals, and new energy [5] Group 2 - The technology sector benefits from the rapid development of AI large models and the trend of domestic chip independence, maintaining high prosperity [5] - The pharmaceutical sector is expected to improve due to optimized policies for innovative drugs and active collaboration from multinational corporations seeking domestic partnerships [5] - The new energy sector is characterized by supply-demand improvements and technological breakthroughs, with the lithium battery industry and photovoltaic sector showing signs of recovery [5] Group 3 - As of September 24, the ChiNext Index has a PE ratio of 45.94x, which is relatively low compared to its historical values and other broad indices like CSI 300, CSI 500, and CSI 1000 [5] - The ChiNext Index remains a key asset for capturing the main line of the bull market, with no signs of bubble formation at the current position, suggesting potential for further investment [5] - Investors are advised to consider a phased accumulation strategy during market corrections for optimal positioning [5] Group 4 - Investors interested in the ChiNext Index can explore the Tianhong ChiNext ETF Connect (A: 001592; C: 001593) through platforms like Alipay, TianTian Fund, and JD Finance [6]

交银国际研究 行业更新 行业评级 领先 2025 年 9 月 25 日 医药行业周报 医保和商保目录调整加速推进，板块回调中择时布局低估优质标的 行业与大盘一年趋势图 资料来源 : FactSet 9/24 1/25 5/25 9/25 -10% 0% 10% 20% 30% 40% 50% 60% 70% 80% 行业表现 恒生指数 丁政宁 Ethan.Ding@bocomgroup.com (852) 3766 1834 诸葛乐懿 Gloria.Zhuge@bocomgroup.com (852) 3766 1845 估值概要 | 公司名称 | 股票代码 | 评级 | 目标价 | 收盘价 | | -----每股盈利----- | ----市盈率---- | | | ----市账率---- 股息率 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | FY25E | | | FY26E FY25E FY26E FY25E FY26E | | | FY25E | | | | | | ( ...

LM-350是基于礼新医药新一代ADC技术平台LM-ADC开发的一款靶向CDH17的ADC，能够高度选择性 地结合CDH17，具有很强的内化能力。LM-350采用IgG1野生型构型，同时具备抗体依赖细胞介导的细 胞毒性作用(ADCC)活性。临床前研究显示，LM-350在多个异种移植模型中表现出显著的抗肿瘤活性， 尤其在对MMAE耐药或伊立替康耐药的结直肠癌细胞中效果突出。 CDH17在多种肿瘤侵袭转移中发挥重要作用，并在约99%的结肠癌、86%的胃腺癌、79%的食管腺癌、 50%的胰腺导管腺癌中高表达。消化道肿瘤(包括结直肠癌、胃癌、胰腺癌、食管癌等)是全球发病率和 死亡率最高的癌症种类之一，2022年全球新发患者数量超过400万人，存在巨大的尚未被满足的临床需 求。 格隆汇9月25日丨中国生物制药(01177.HK)公告，公司全资附属公司礼新医药科技(上海)有限公司("礼新 医药")自主研发的国家1类创新药LM-350"CDH17抗体偶联药物(ADC)"在澳洲开展的I期临床试验已顺利 完成首例患者入组，标志着这一创新疗法正式进入临床开发阶段。 ...

Core Viewpoint - Since September 24 of last year, the performance of public funds has rebounded significantly, with nearly 90% of funds achieving positive returns, and many funds seeing substantial gains exceeding 100% and even 200% [1][6]. Fund Performance Summary - The average return of various fund indices has exceeded 50%, with the ordinary stock fund index leading at a 60.33% increase [6]. - Notable funds include: - Debon Xin Xing Value Flexible Allocation Mixed A with a return of 271.51% - CITIC Construction Investment North Exchange Selected Two-Year Open Mixed A at 268.41% - Other funds with returns over 200% include China Europe Digital Economy Mixed Initiation A and Yongying Advanced Manufacturing Intelligent Selection Mixed Initiation A [4][6]. Market Outlook - Current index levels are at a phase high, suggesting a potential for sideways market movement, but structural opportunities remain [5][8]. - Key areas for investment include sectors aligned with industrial development trends, such as artificial intelligence, innovative pharmaceuticals, and new consumption [8]. - The rapid advancement of industrial upgrades and the release of policy dividends are expected to provide ongoing upward momentum for the A-share market [8]. - The stability of Sino-U.S. relations is anticipated to reduce overseas policy risk, creating a favorable environment for the domestic equity market in the coming quarters [8].

Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. is actively expanding its presence in the senior health sector, focusing on chronic disease management and developing products tailored for elderly health needs [2][3]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and went public on March 1, 2023. The company is primarily engaged in pharmaceutical agency, retail, and terminal procurement, with its main revenue derived from traditional Chinese and Western medicine, accounting for 97.60% of total revenue [7]. - As of June 30, 2023, the company had 26,100 shareholders, an increase of 45.15% from the previous period, with an average of 5,725 circulating shares per person, a decrease of 31.10% [8]. Financial Performance - For the first half of 2023, the company achieved a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%. The net profit attributable to shareholders was 104 million yuan, up 42.17% year-on-year [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [8]. Market Position and Shareholder Structure - The company has a market capitalization of 5.132 billion yuan, with a trading volume of 57.7375 million yuan and a turnover rate of 3.00% on September 25, 2023 [1]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company, and there are collaborations with various Alibaba platforms [3]. Strategic Initiatives - The company is focusing on the senior health market by providing chronic disease training and services through pharmacies, enhancing health consultation and medication guidance for the elderly [2]. - It is developing a series of products aimed at common diseases in the elderly, including the "Fuman Medical" series for cardiovascular health and the "Guojin" series of traditional Chinese medicine health products [2][3].

Core Viewpoint - 康龙化成 is benefiting from the CRO concept, innovative drugs, smart healthcare, and the depreciation of the RMB, with a focus on digital transformation in clinical services through AI technology [2][3]. Company Overview - 康龙化成 (Beijing) New Drug Technology Co., Ltd. specializes in integrated drug research, development, and production services, covering the entire process from drug discovery to development [2][7]. - The company's main revenue sources include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and other services [7]. Financial Performance - For the first half of 2025, 康龙化成 achieved revenue of 6.441 billion yuan, a year-on-year increase of 14.93%, while net profit attributable to shareholders decreased by 37% to 701 million yuan [8]. - As of June 30, 2025, overseas revenue accounted for 84.95% of total revenue, benefiting from the depreciation of the RMB [3]. Market Activity - On September 25, 康龙化成's stock rose by 0.96%, with a trading volume of 1.288 billion yuan and a market capitalization of 61.526 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net inflow of 41.526 million yuan on the day [4][5]. Strategic Initiatives - The establishment of a "Digital Innovation Technology Department" aims to enhance digital transformation in clinical research services, leveraging AI and automation to improve efficiency and reduce costs [3]. - The acquisition of Shanghai Jiying is expected to further advance the company's digital transformation in clinical services [2].

恒生港股通创新药指数通过在编制方案中剔除CXO，成为ETF跟踪的指数中首批"纯度"100%的创新药 指数，更加精准地反映我国创新药企的整体表现。目前，恒生创新药ETF（159316）是市场唯一跟踪该 指数的产品，可助力投资者精准布局创新药产业发展机遇。 昨日，恒瑞医药宣布与全球制药公司Glenmark达成独家许可协议，将其自主研发的HER2 ADC药物瑞康 曲妥珠单抗(1811)在除中、美、欧、日等核心市场外的全球权益授权给Glenmark，并收取1800万美元首 付款及最高10.93亿美元的潜在里程碑付款。 有分析认为，恒瑞医药HER2 ADC药物的海外授权交易证明中国创新药企已具备全球竞争力，此次交易 打破了近期创新药板块缺乏BD事件催化的平淡局面，加之即将到来的欧洲肿瘤内科学会及第四季度传 统BD交易高频期，市场对后续BD事件预期升温，有望开启新一轮创新药行情。 港股创新药板块午后维持红盘震荡，截至14:45，恒生港股通创新药指数上涨0.6%，云顶新耀涨超5%， 乐普生物-B涨超3%，康方生物、恒瑞医药等多股涨超1%，此前连续3日"吸金"的恒生创新药ETF （159316）盘中再获2100万份净申购。 ...

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 and listed in 2010, Hepalink operates primarily in the heparin industry, with its main business segments including formulations (63.06%), CDMO (18.59%), and heparin raw materials (16.05%) [7]. - As of June 30, 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization of Hepalink is 17.666 billion yuan, with a trading volume of 37.9727 million yuan on September 25, 2023 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300, with the average circulating shares per person remaining at zero [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On September 25, 2023, the stock price of Hepalink fell by 1.15%, with a turnover rate of 0.25% [1]. - The stock is currently near a resistance level of 12.33 yuan, with an average trading cost of 11.57 yuan [6].

Core Viewpoint - The article discusses the significant growth of the Hong Kong innovative drug sector, which has seen indices rise over 100% this year, and emphasizes the importance of understanding the underlying companies rather than just focusing on standout products [2][4]. Group 1: Research Perspective - The research approach taken by Chen Jialin focuses on the governance structure of companies, which is crucial for identifying sustainable growth and avoiding potential pitfalls [5][17]. - Chen emphasizes the importance of filtering out noise from public information while still valuing the insights gained from company reports and management discussions [6][7]. - The need to consider the buyer's perspective in the BD (business development) model is highlighted, as issues with large overseas buyers could impact the Chinese innovative drug market [7][60]. Group 2: Market Dynamics - The innovative drug sector is currently experiencing a phase of structural differentiation, with a shift towards capturing alpha opportunities as the market stabilizes after a period of rapid growth [4][12]. - The article notes that the innovative drug industry is in a long-term growth trajectory, with significant potential for returns, particularly in the context of global market dynamics and China's increasing share in the sector [14][66]. - Chen points out that the current market environment is characterized by high uncertainty, which poses challenges for sustaining excess returns [16][70]. Group 3: Investment Strategy - The investment strategy discussed involves a balanced approach between aggressive and defensive positions, with a focus on minimizing errors rather than chasing opportunities [9][10]. - Chen advocates for a trading strategy that capitalizes on human behavioral biases, allowing for the identification of mispriced opportunities in the market [42][43]. - The importance of understanding the broader geopolitical and economic landscape is emphasized, as these factors can significantly influence market conditions and investment outcomes [16][66]. Group 4: Future Outlook - The article suggests that the current phase of the BD model is not yet complete, with ongoing developments in the innovative drug sector expected to yield further opportunities [64][65]. - Chen expresses optimism about the future of Chinese innovative drug companies, citing their competitive advantages in R&D efficiency and market access [68][69]. - The potential risks associated with external factors, such as regulatory changes and market sentiment, are acknowledged, but the overall trend remains positive for the sector [60][63].

Group 1 - The core viewpoint of the news highlights the continued upward trend in the server and semiconductor wafer sectors, with significant increases in various indices related to the Science and Technology Innovation Board (科创板) [1] - The Shanghai Stock Exchange Science and Technology Innovation Board 50 Index rose by 1.8%, while the Science and Technology Innovation Board Growth Index and the Science and Technology Innovation Comprehensive Index increased by 1.2% and 0.4%, respectively [1] - The trading volume of the Science and Technology Innovation Board 50 ETF (588080) exceeded 1 billion yuan during the morning session, with its latest scale reaching 74.4 billion yuan, making it the largest ETF related to the Science and Technology Innovation Board [1] Group 2 - The Science and Technology Innovation Board 50 ETF tracks the top 50 stocks on the board, characterized by high market capitalization and liquidity, with over 60% of its composition in the semiconductor sector [3] - The rolling price-to-earnings ratio of the Science and Technology Innovation Board 50 Index is reported at 188.4 times, with a valuation percentile of 99.9% since its inception [3] - The Science and Technology Innovation Board 100 Index, which focuses on medium-sized stocks, saw a 0.4% increase, with a significant representation from the electronics and biopharmaceutical sectors [3] Group 3 - The Science and Technology Innovation Comprehensive Index, which covers all market securities on the board, increased by 1.2%, with a rolling price-to-earnings ratio of 272.9 times [3] - The Science and Technology Innovation Growth 50 ETF, which tracks high-growth stocks, also reported a 1.2% increase, with a rolling price-to-earnings ratio of 228.7 times [3]